Since the United States Food and Drugs Administration (FDA) declined to approve tofacitinib for moderate-to-severe psoriasis, permitting it only to be used in psoriatic arthritis, reumatological arthritis and ulcerative colitis, due to additional safety analysis requirement [49,62,63,64,65], the interplay between JAK/STAT inhibitors and gut microbiome in psoriatic patients still remains unknown. Here, SOAT1 is linked to psoriatic arthritis.